To produce the Chinese vaccine, the Sinovac laboratory has just opened a third production line which allows it to achieve an annual production of 2 billion doses.
CoronaVac is one of the four antidotes approved by the Chinese government. During the various studies carried out in Brazil, its effectiveness rose to 50% to prevent contamination and it was evaluated at 80% to avoid hospitalization. In a press release, the Sinovac laboratory specifies that it has set up a third production line. The Chinese group is therefore able to produce 2 billion annual doses. For this vaccine, only two doses are needed per person.
“Data is missing”
The pharmaceutical company says it has delivered nearly 200 million doses in more than 20 countries including China. Sinovac adds that it has obtained authorizations to market its serum in more than thirty countries. On Wednesday March 31, WHO experts stressed that the doses of Sinovac and its compatriot Sinopharm were safe and effective against Covid-19. However, more data is needed before recommending their application. “There is a lack of data (…) with regard to the elderly and those suffering from other diseases”, said the World Health Organization’s Strategic Advisory Group of Experts (SAGE) on immunization.
